FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePercheron Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PER.AX
Percheron Therapeutics Limited Stock AnalysisComprehensive stock analysis for Percheron Therapeutics Limited (PER.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPER.AX
PER.AX
Percheron Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PER.AX
  1. Home
  2. Stocks
  3. Percheron Therapeutics Limited

Percheron Therapeutics Limited

🇦🇺PER.AX•ASX

Percheron Therapeutics Limited

🇦🇺PER.AX•ASX

Your view on PER.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Percheron Therapeutics Limited

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
James Garner
Headquarters
L30, Collins Place, Melbourne, VIC, AU
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
James Garner
Headquarters
L30, Collins Place, Melbourne, VIC, AU
Description

Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio.

This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma.

Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Percheron Therapeutics Limited. Starting points for Percheron Therapeutics Limited: beta 1.03 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Percheron Therapeutics Limited. Percheron Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Percheron Therapeutics Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Percheron Therapeutics Limited. Percheron Therapeutics Limited has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PER.AX12 companies
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
HMPQHempAmericana, IncHealthcareOTC$291,753
HPMMHemp Naturals, Inc.HealthcareOTC$174,630
CRDLCardiol Therapeutics Inc.HealthcareNASDAQ$104.1M
CRDL.TOCardiol Therapeutics Inc.HealthcareTSX$147.2M
CRFTFBC Craft Supply Co. Ltd.HealthcareOTC$23
CRLBFCresco Labs Inc.HealthcareOTC$350.4M
CRONCronos Group Inc.HealthcareNASDAQ$1.1B
CRON.TOCronos Group Inc.HealthcareTSX$1.6B
CRYMCryomass Technologies Inc.HealthcareOTC$47,432
CSTFCuraScientific CorpHealthcareOTC$377,345
CSWYFChina Shineway Pharmaceutical Group LimitedHealthcareOTC$758.4M
CSWYYChina Shineway Pharmaceutical Group LimitedHealthcareOTC$36.4M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Percheron Therapeutics Limited. Coverage tracks Percheron Therapeutics Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Percheron Therapeutics Limited.

PER.AX AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1